INmune Bio (NASDAQ:INMB) Earns Buy Rating from Analysts at Alliance Global Partners

Alliance Global Partners initiated coverage on shares of INmune Bio (NASDAQ:INMB) in a research report released on Monday morning, Marketbeat reports. The firm issued a buy rating and a $20.00 target price on the stock.

A number of other research analysts have also weighed in on the stock. Scotiabank started coverage on shares of INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price for the company. Raymond James assumed coverage on shares of INmune Bio in a research note on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective for the company.

INmune Bio Stock Performance

INMB opened at $5.00 on Monday. The stock has a market capitalization of $98.91 million, a price-to-earnings ratio of -2.60 and a beta of 1.85. The company has a fifty day moving average of $5.78 and a 200 day moving average of $7.99. INmune Bio has a fifty-two week low of $4.78 and a fifty-two week high of $14.74.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, August 1st. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%. On average, equities research analysts forecast that INmune Bio will post -2.14 earnings per share for the current year.

Insider Activity at INmune Bio

In other news, CEO Raymond Joseph Tesi acquired 15,380 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was bought at an average cost of $6.38 per share, with a total value of $98,124.40. Following the completion of the purchase, the chief executive officer now directly owns 1,554,106 shares of the company’s stock, valued at $9,915,196.28. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other INmune Bio news, CFO David J. Moss acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average price of $5.29 per share, for a total transaction of $52,900.00. Following the acquisition, the chief financial officer now directly owns 1,285,869 shares in the company, valued at $6,802,247.01. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Raymond Joseph Tesi acquired 15,380 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $6.38 per share, for a total transaction of $98,124.40. Following the transaction, the chief executive officer now directly owns 1,554,106 shares in the company, valued at $9,915,196.28. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 33,070 shares of company stock worth $200,087. Company insiders own 35.20% of the company’s stock.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently made changes to their positions in INMB. CVI Holdings LLC purchased a new position in INmune Bio in the 2nd quarter worth about $5,260,000. Marshall Wace LLP raised its stake in shares of INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after acquiring an additional 89,091 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of INmune Bio by 124.6% in the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after purchasing an additional 32,511 shares during the period. Westside Investment Management Inc. grew its stake in INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after purchasing an additional 10,950 shares in the last quarter. Finally, Fermata Advisors LLC grew its stake in INmune Bio by 25.2% in the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after purchasing an additional 8,590 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.